News & Updates
Showing Neurology articles
Showing
GLP-1RA exposure lowers mortality in patients with dementia
The use of glucagon-like peptide-1 receptor agonist (GLP-1RA) appears to prevent all-cause deaths among patients with dementia, as shown in a retrospective cohort study presented at AAIC 2026.
GLP-1RA exposure lowers mortality in patients with dementia
25 Jul 2026
Blood test enables physicians to rule out Alzheimer’s disease in primary care
A blood-based biomarker (BBM) test for Alzheimer’s disease (AD) allows primary care physicians to diagnose AD with the same precision as specialists, suggests a study presented at AAIC 2026.
Blood test enables physicians to rule out Alzheimer’s disease in primary care
24 Jul 2026
Novel BTK inhibitor on par with ocrelizumab in reducing disability progression in PPMS
The investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib demonstrates its noninferiority to ocrelizumab in reducing the risk of disability progression in patients with primary progressive multiple sclerosis (PPMS) in the phase III FENtrepid study.
Novel BTK inhibitor on par with ocrelizumab in reducing disability progression in PPMS
17 Jul 2026
Older age, overweight raise risk of symptomatic VTE in DFF patients
A Singapore study has observed a high prevalence of symptomatic venous thromboembolism (VTE) in patients who underwent distal femur fracture (DFF) surgery. Those with advanced age or who are overweight are more likely to develop symptomatic VTE.
Older age, overweight raise risk of symptomatic VTE in DFF patients
16 Jul 2026
Functional outcome improvements with atogepant sustained until 3 years
A 156-week safety extension study presented at EAN 2026 shows the first 3-year long-term results for atogepant in the preventive treatment of migraine in individuals with chronic migraine (CM) or episodic migraine (EM) who had an insufficient response to 2–4 classes of conventional oral, non-migraine-specific preventive migraine treatments.